Cancer-fighting antibody drugs are designed to penetrate tumor cells and release a lethal payload deep within, but too often ...

Cambridge life science business AbOliGo, which is supporting researchers in spatial and single-cell analysis worldwide, has ...

ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including ...

Discusses New Strategy and Business Plan Focused on Commercialization and Liquid Biopsy Innovation November 26, 2025 9:00 ...

On5, 2025, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or ...

November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...

The federal government shutdown meant that the Securities & Exchange Commission (SEC), which oversees listing processes in ...

Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or ...

The main market opportunities in tissue factor-targeted immunotherapies include developing advanced ADCs for cancers with high TF expression like NSCLC, pancreatic, and head and neck cancers. The ...

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and ...

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board ...